Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Single-Cell Analysis of Immune Recognition in Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitor Discontinuation

Blood (2023) 142 (Supplement 1): 3146.

https://doi.org/10.1182/blood-2023-185630

Published: 2023

Journal Articles

Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS

Blood (2021) 138 (Supplement 1): 801.

https://doi.org/10.1182/blood-2021-147150

Published: 2021

Journal Articles

Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia

Jani Huuhtanen, Jason Theodoropoulos, BSc, Rebecca Warfvinge, MSc, Andreas Burchert, MD, Tiina Kasanen, Jay Klievink, MSc, Shady Adnan Awad, MD, Olli Dufva, MD, Mette Ilander, PhD, Taina Jaatinen, Ulla Olsson-Strömberg, MD PhD, Henrik Hjorth-Hansen, MD, Göran Karlsson, PhD, Harri Lähdesmäki, PhD, Anna Kreutzman, PhD, Satu Mustjoki, MD PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139134

Published: 2020

Journal Articles

Identification of Somatic Mutations in Expanded T Cell Clones of Patients with Chronic Graft-Versus-Host Disease (GVHD)

Giljun Park, PhD, Daehong Kim, Sofie Lundgren, Rajiv K Khajuria, Ana M Hurtado, Cecilia Muñoz-Calleja, Dra, Laura Cardeñoso, Samuli Eldfors, Pekka Ellonen, Sari Hannula, Oscar Brück, Anna Kreutzman, PhD, Andres Jerez, Maija Itälä-Remes, MD PhD, Mikko A Keränen, MD PhD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 4487.

https://doi.org/10.1182/blood.V130.Suppl_1.4487.4487

Published: 2017

Journal Articles

Plasma Fms-Related Tyrosine Kinase 3 Ligand (Flt3L) Levels at Diagnosis Correlate with Treatment Response in Chronic Myeloid Leukemia

Bhagwan Yadav, PhD, Mette Ilander, PhD, Anna Kreutzman, PhD, Henrik Hjorth-Hansen, MD, Satu Mustjoki, MDPhD

Blood (2017) 130 (Supplement 1): 1602.

https://doi.org/10.1182/blood.V130.Suppl_1.1602.1602

Published: 2017

Journal Articles

Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment

Anna Kreutzman, PhD, Perttu Koskenvesa, MD, Kasanen Tiina, Ulla Olsson-Strömberg, MD PhD, Jesper Stentoft, MD PhD, Leif Stenke, MD PhD, Lene Udby, MD, Bjorn T. Gjertsen, MD PhD, Kourosh Lotfi, MD, Berit Markevän, MD PhD, Jeroen Janssen, MD, Tim Brümmendorf, MD, Johan Richter, MD, Henrik Hjorth-Hansen, MD PhD, Satu Mustjoki, MD PhD

Blood (2016) 128 (22): 3069.

https://doi.org/10.1182/blood.V128.22.3069.3069

Published: 2016

Journal Articles

Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression

Valentín García-Gutierrez, Beatriz Colom-Fernandez, Anna Kreutzman, PhD, Luis Felipe Casado, Fermín Sánchez-Guijo, MD, Rosa M. Ayala, MD PhD, Concepcion Boque, PhD, Blanca Xicoy, MD PhD, Isabel Montero, MD, Cesar Soto, Raquel De Paz, Joaquin Martinez Lopez, MDPhD, Cecilia Muñoz-Calleja, Juan Luis Steegmann, MD

Blood (2015) 126 (23): 4015.

https://doi.org/10.1182/blood.V126.23.4015.4015

Published: 2015

Journal Articles

The Role of CMV Serostatus of the Donor in the Graft Lymphoid Composition and Prediction of Gvhd and CMV Reactivation

Anna Kreutzman, PhD, Itxaso Portero Sainz, MSc, Valle Gomez Garcia De Soria, MD PhD, Carlos Fernandez, MD, Royg Mercedes, MD, Ana Marcos, MSc, Beatriz Colom Fernandez, MSc, Ana Ramirez, Laura Cardeñoso, MD PhD, Rafael De La Camara, MD, Cecilia Muñoz Calleja, MD PhD

Blood (2014) 124 (21): 2422.

https://doi.org/10.1182/blood.V124.21.2422.2422

Published: 2014

Journal Articles

CCR7 As a New Biomarker in Graft-Versus-Host Disease: T Cells Expressing the Homing Receptor CCR7 Mediate the Pathogenesis of Gvhd

Itxaso Portero, Valle Gomez, MD, Carlos Arandojo, MD, Anna Kreutzman, PhD, Mercedes Royg, MD, Ana Ramirez, Ana Marcos, MSc, Rafael De La Camara, MD, Cecilia Muñoz, MD PhD

Blood (2014) 124 (21): 3930.

https://doi.org/10.1182/blood.V124.21.3930.3930

Published: 2014

Journal Articles

NK-Cells In Dasatinib-Treated Chronic Myeloid Leukemia Patients Display a Unique Phenotype Associated With Cytotoxic Potential

Beatriz Colom Fernandez, Anna Kreutzman, PhD, Valentin Garcia, MD, PhD, Maria José Requena Rodríguez, MD, Raúl Córdoba Mascuñano, MD, Begoña Maestro Gutiérrez, Juan Luis Steegmann, MD, Cecilia Muñoz Calleja, MD, PhD

Blood (2013) 122 (21): 1475.

https://doi.org/10.1182/blood.V122.21.1475.1475

Published: 2013

Journal Articles

Chronic Myeloid Leukemia Patients Undergoing Interferon Alpha Therapy Exhibit Normal Peripheral Blood Gamma Delta T Cells That May Be Expanded in Vitro to Generate Predominantly CD45RA-Positive Effector Memory Cells for Immunotherapy

Gabrielle Melanie Siegers, PhD, Anna Kreutzman, PhD, Mette Matilda Ilander, MSc, Satu Mustjoki, MD, PhD, Lynne Marie Postovit, PhD

Blood (2012) 120 (21): 3729.

https://doi.org/10.1182/blood.V120.21.3729.3729

Published: 2012

Journal Articles

Functional Characterization of T- and NK-Cells in Chronic Myeloid Leukemia Patients Treated with Interferon-α Monotherapy.

Mette Matilda Ilander, MSc, Anna Kreutzman, PhD, Peter Rohon, MD, Teresa Melo, MD, Edgar Faber, MD, PhD, Kimmo Porkka, MD, PhD, Jukka Vakkila, MD, PhD, Satu Mustjoki, MD, PhD

Blood (2012) 120 (21): 2782.

https://doi.org/10.1182/blood.V120.21.2782.2782

Published: 2012

Journal Articles

Dasatinib Has a Dual Mode of Action: Direct BCR-ABL1 Mediated Anti-Leukemic Effects Are Complemented by Promotion of Th1-Type and NK-Cell Mediated Cellular Immune Responses,

Anna Kreutzman, MSc, Jukka Vakkila, MD, PhD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD

Blood (2011) 118 (21): 3760.

https://doi.org/10.1182/blood.V118.21.3760.3760

Published: 2011

Journal Articles

Interferon Alpha Treated Patients with Chronic Myeloid Leukemia (CML) In Prolonged Complete Remission Have Increased Numbers of NK-Cells and Clonal Gamma-Delta T-Cells, and a Distinct Plasma Cytokine Profile.

Anna Kreutzman, MSc, Peter Rohon, MD, Edgar Faber, MD, PhD, Karel Indrak, MD, PhD, Vesa Juvonen, PhD, Veli Kairisto, MD, PhD, Jaroslava Voglova, MD, Marjatta Sinisalo, MD, PhD, Emilia Flochova, MD, PhD, Petteri Arstila, MD, PhD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD

Blood (2010) 116 (21): 1201.

https://doi.org/10.1182/blood.V116.21.1201.1201

Published: 2010

Journal Articles

Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated with Prolonged Therapy Responses In Advanced Leukemia.

Satu Mustjoki, MD, PhD, Philippe Rousselot, MD, PhD, Sari Jalkanen, Msc, Anna Kreutzman, MSc, Teresa Melo, MD, Anna-Maria Lahesmaa, MSc, Sampsa Hautaniemi, PhD, Mathieu Molimard, MD, PhD, Richard Smykla, PhD, Francis Lee, PhD, Jukka Vakkila, MD, PhD, Kimmo Porkka, MD, PhD

Blood (2010) 116 (21): 1204.

https://doi.org/10.1182/blood.V116.21.1204.1204

Published: 2010

Journal Articles

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy

Anna Kreutzman, Vesa Juvonen, Veli Kairisto, Marja Ekblom, Leif Stenke, Ruth Seggewiss, Kimmo Porkka, Satu Mustjoki

Blood (2010) 116 (5): 772–782.

https://doi.org/10.1182/blood-2009-12-256800

Published: 2010

Journal Articles

Mono/Oligoclonal T and NK Cells Are Common in Philadelphia Chromosome Positive (Ph+) Leukemia Patients at Diagnosis and Expand During Successful Tyrosine Kinase Inhibitor Therapy.

Anna Kreutzman, MSc, Vesa Juvonen, PhD, Veli Kairisto, MD, PhD, Marja Ekblom, MD, PhD, Leif Stenke, MD, PhD, Ruth Seggewiss, MD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD

Blood (2009) 114 (22): 856.

https://doi.org/10.1182/blood.V114.22.856.856

Published: 2009

Journal Articles

Large Granular Lymphocyte (LGL) Expansions Comprising Oligoclonal T Cell or NK Cell Populations in Dasatinib Treated Patients Are Associated with HLA-A*0201, CMV Reactivation and Enhanced Anti-Leukemic Control.

Satu Mustjoki, MD, PhD, Anna Kreutzman, MSc, Carolin Dix, David A Price, MRCP, DPhil, Kristin Ladell, MD, Marja Ekblom, MD, PhD, Leif Stenke, MD, PhD, Hermann Einsele, MD, Kimmo Porkka, MD, PhD, Ruth Seggewiss, MD

Blood (2009) 114 (22): 1123.

https://doi.org/10.1182/blood.V114.22.1123.1123

Published: 2009

Journal Articles

Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy

Blood (2008) 112 (11): 573.

https://doi.org/10.1182/blood.V112.11.573.573

Published: 2008

NARROW

Single-Cell Analysis of Immune Recognition in Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitor Discontinuation

Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS

Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia

Identification of Somatic Mutations in Expanded T Cell Clones of Patients with Chronic Graft-Versus-Host Disease (GVHD)

Plasma Fms-Related Tyrosine Kinase 3 Ligand (Flt3L) Levels at Diagnosis Correlate with Treatment Response in Chronic Myeloid Leukemia

Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment

Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression

The Role of CMV Serostatus of the Donor in the Graft Lymphoid Composition and Prediction of Gvhd and CMV Reactivation

CCR7 As a New Biomarker in Graft-Versus-Host Disease: T Cells Expressing the Homing Receptor CCR7 Mediate the Pathogenesis of Gvhd

NK-Cells In Dasatinib-Treated Chronic Myeloid Leukemia Patients Display a Unique Phenotype Associated With Cytotoxic Potential

Chronic Myeloid Leukemia Patients Undergoing Interferon Alpha Therapy Exhibit Normal Peripheral Blood Gamma Delta T Cells That May Be Expanded in Vitro to Generate Predominantly CD45RA-Positive Effector Memory Cells for Immunotherapy

Functional Characterization of T- and NK-Cells in Chronic Myeloid Leukemia Patients Treated with Interferon-α Monotherapy.

Dasatinib Has a Dual Mode of Action: Direct BCR-ABL1 Mediated Anti-Leukemic Effects Are Complemented by Promotion of Th1-Type and NK-Cell Mediated Cellular Immune Responses,

Interferon Alpha Treated Patients with Chronic Myeloid Leukemia (CML) In Prolonged Complete Remission Have Increased Numbers of NK-Cells and Clonal Gamma-Delta T-Cells, and a Distinct Plasma Cytokine Profile.

Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated with Prolonged Therapy Responses In Advanced Leukemia.

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy

Mono/Oligoclonal T and NK Cells Are Common in Philadelphia Chromosome Positive (Ph+) Leukemia Patients at Diagnosis and Expand During Successful Tyrosine Kinase Inhibitor Therapy.

Large Granular Lymphocyte (LGL) Expansions Comprising Oligoclonal T Cell or NK Cell Populations in Dasatinib Treated Patients Are Associated with HLA-A*0201, CMV Reactivation and Enhanced Anti-Leukemic Control.

Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only